SPECT/CT guided treatment for postural abnormalities in Parkinson's disease

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050591

Enrollment

Unknown

Registered

2021-09-01

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postural abnormalities in Parkinson's disease

Interventions

Experimental group:The treatment of botulinum toxin under the guidance of SPECT

Control group:The treatment of botulinum toxin without the guidance of SPECT

Eligibility

Sex/Gender

All

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 40 to 80 years; 2. PD patients meet the PD diagnostic criteria established by the International Movement Disorder Society (MDS) in 2016. 3. Abnormal trunk posture; 4. The subjects clearly understand the purpose of the research, are willing and able to abide by the requirements to complete the research, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe lung, liver, kidney, immune system and blood system diseases; 2. Patients with severe cognitive impairment or mental illness that affect the execution or evaluation of the trial, or drug dependence; 3. The presence of other dystonias.

Design outcomes

Primary

Measure	Time frame
Improvement of abnormal trunk posture;	—

Countries

China

Contacts

Public ContactGuan Qiang

Shanghai Tongji Hospital

Guanqianglu@126.com+86 13661421451

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026